“Site Selection for Life Sciences Companies in Europe” report debuts

In California, KPMG, Venture Valuation and EuropaBio released their  “Site Selection for Life Sciences Companies in Europe” report at the BIO International Convention. The third edition of the report offers a comprehensive and unique overview of the various aspects relevant for smart companies’ site selection, such as size and specialization of the life sciences clusters, business-friendly legislation, macroeconomics and, importantly, the tax system. This combination of operational aspects and tax considerations gives life science companies a clear insight of how new or redesigned value chains can influence location selection.

According to the report, there are three types of European countries in the Life Science space:

1. Countries with strong clusters of life science companies and an attractive tax and business environment
2. Countries that have significant clusters of life science companies in their jurisdictions, but lack the benefits of an attractive business environment
3. Countries which have attractive business and tax regimes without the support of a strong domestic biopharmaceutical industry

EuropaBio represents 77 corporate and associate members and bio regions, and 16 national biotechnology associations in turn representing over 1800 biotech SMEs.

More on the story.